Literature DB >> 26011327

Urothelial carcinoma: Recurrence and risk factors.

Bogomir Milojevic1, Zoran Dzamic, Boris Kajmakovic, Dragica Milenkovic Petronic, Sandra Sipetic Grujicic.   

Abstract

Urothelial carcinomas are malignant tumors that arise from the urothelial epithelium and may involve the lower and upper urinary tract. They are characterized by multiple, multifocal recurrences throughout the genitourinary tract. Bladder tumors account for 90-95% of urothelial carcinomas and are the most common malignancies of the urinary tract. Upper urinary tract urothelial carcinomas (UTUC) are relatively rare, accounting for 5% of urothelial tumors. The incidence of subsequent bladder cancer after surgical treatment for UTUC is approximately 15-50%. In contrast, patients with a primary tumor of the bladder have a low risk (2-6%) the development of UTUC. Identification of prognostic factors and early detection of recurrent disease provide a better strategy for postoperative monitoring, surveillance, and potentially improve patient outcomes. In this review study we discuss the main risk factors for UTUC recurrence after radical cystectomy, and risk factors for intravesical recurrence after radical nephroureterectomy.

Entities:  

Mesh:

Year:  2015        PMID: 26011327

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

1.  BLCA1 expression is associated with angiogenesis of bladder cancer and is correlated with common pro-angiogenic factors.

Authors:  Chenchen Feng; Lujia Wang; Guanxiong Ding; Haowen Jiang; Qiang Ding; Zhong Wu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Auxiliary diagnostic value of p16 amplification combined with the detection of heterozygous and homozygous loss for urothelial carcinoma.

Authors:  Xiaopeng Mao; Baimou Li; Ying Liang; Shuhua Li; Jianwen Zhou; Qiong He; Neng Jiang; Yangshan Chen; Yu Sun; Yongmei Cui; Wenting Jiang; Han Wang; Liantang Wang; Zunfu Ke
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

3.  Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.

Authors:  Zhi-Hua Liu; Fu-Fu Zheng; Yu-Ling Mao; Lie-Fu Ye; Jun Bian; De-Hui Lai; Yun-Lin Ye; Yu-Ping Dai
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

4.  Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.

Authors:  Ming Sun; Zhaofu Chen; Shutao Tan; Caigang Liu; Wenyan Zhao
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

5.  A rare occurrence of a metastatic urothelial carcinoma to the thoracic vertebra: A case report.

Authors:  May Zaw Soe; Chin Pei Bong; Shankaran Thevarajah; Kai Ming Teah; Boon Tat Yeap
Journal:  Ann Med Surg (Lond)       Date:  2022-01-25

6.  Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.

Authors:  Ying-Li Lin; Yan-Ling Wang; Xing-Li Fu; Wen-Ping Li; Yu-Hao Wang; Jian-Guo Ma
Journal:  Oncotarget       Date:  2016-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.